XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Collaboration Agreements,License Agreement and Revenues - Drug Product Revenue - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jun. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized   $ 235,309 $ 176,319 $ 256,577
Deferred Revenue   15,857 6,547  
Royalty Revenue [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Deferred Revenue   200    
Drug Product Revenue [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized   962 8,906 (36,324)
Drug Product Revenue [Member] | Astellas Agreement        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized   3,186 4,281 $ (36,324)
Drug Product Revenue [Member] | Japan [Member]        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized $ 8,200      
Drug Product Revenue [Member] | Europe [Member] | Astellas Agreement        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Deferred Revenue   11,800    
Bulk Drug Product | Europe [Member] | Astellas Agreement        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Deferred Revenue     $ 6,000  
Bulk Drug Product | Europe [Member] | E U Supply And Astellas Agreement        
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]        
Drug product revenue recognized   8,300    
Burdened manufacturing costs   $ 1,000